To Top

Search By Topic

Cell and Gene Therapy

68 Articles available
Cell and Gene Therapy

MedImmune and 4D Molecular Therapeutics Collaborate to Design, Develop and Commercialize AAV Gene Therapy for Chronic Lung Disease

PR-M07-18-NI-038
Investment

Evonetix Awarded Innovate UK Funding for £1.3 Million Gene Synthesis Project

PR-M07-18-NI-023
Genome

Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs

PR-M06-18-NI-093
Genome

Johnson & Johnson Innovation Opens JLABS @ NYC in Collaboration with New York State and the New York Genome Center

PR-M06-18-NI-075
Cell and Gene Therapy

Will Rapid Genome Sequencing Become A Standard Practice for Acutely Ill Infants?

PAO-M06-18-NI-012
Cell and Gene Therapy

BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders

PR-M06-18-NI-052
Cell and Gene Therapy

StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform

PR-M06-18-NI-054
Drug Discovery

Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts

PR-M06-18-NI-044
Cell and Gene Therapy

Global Gene Therapy Market Opportunity Analysis and Industry Forecast, 2023

PR-M06-18-NI-043
Viral Vector

Flexible, Mobile, Modular: High-Containment Viral Vector Center of Excellence

PAP-Q2-18-CL-005
Cell and Gene Therapy

Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing

PAP-Q2-18-CL-011
Cell and Gene Therapy

Editas Founders Start New Gene Editing Company

PAO-M05-18-NI-011
FDA Guidance

FDA finalizes guidances to accelerate the development of reliable, beneficial next generation sequencing-based tests

PR-M04-18-NI-54
Drug Discovery

"Transcriptional wiring" of cancer genes can be resolved using Lexogen's SLAMseq and QuantSeq technologies to facilitate drug discovery

PR-M04-18-NI-38
Cell and Gene Therapy

New Stem Cell Therapy Approved in Europe

PR-M03-18-NI-102
Discovery

New ALS Gene Discovered: KIF5A

PR-M03-18-NI-091
Partnership

Nohla Therapeutics Selects Advanced Therapies Business Unit of WuXi AppTec to Manufacture Universal Donor Cell Therapies

PR-M03-18-NI-090
Capacity Expansion

Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion

PR-M03-18-NI-079
Cell and Gene Therapy

Oxford BioMedica is Making Big Moves

PAO-M03-18-NI-012
Viral Vector

Ensuring Confidence in Viral Vector Manufacturing

PAP-Q1-18-CL-012
Cell and Gene Therapy

MeiraGTx Receives EMA PRIME Designation for Achromatopsia Gene Therapy Candidate

PR-M03-18-NI-022
Cell and Gene Therapy

Brammer Bio Supports Rare Disease Day 2018

PR-M03-18-NI-006
Oncology

Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

PR-M02-18-NI-95
Market Expansion

Marken Accelerates Its Reach And Growth In Clinical Trial Logistics

PR-M02-18-NI-031
Financing

Engine Biosciences Raises $10 Million in Seed Financing to Accelerate Drug Discovery Using Genomics and Artificial Intelligence

PR-M02-18-NI-015
Cell and Gene Therapy

Cell Therapy Companies Can Now Have Improved Cell Thawing Capabilities

PAO-M01-18-NI-042
FDA Approval

U.S. FDA Approves LYNPARZA® (olaparib) in Germline BRCA-Mutated Metastatic Breast Cancer

PR-M01-18-NI-052
FDA

FDA Approves First Treatment for Breast Cancer with a Certain Inherited Genetic Mutation

PR-M01-18-NI-047
Announcement

Taxus Cardium Announces Name Change To Gene Biotherapeutics

PR-M01-18-NI-021
Biologics

New Class of Exosome Biologics Focuses on Stroke Treatment

PAO-M01-18-NI-011
CRISPR

Genetically Engineered Horses Could be a Reality

PAO-M01-18-NI-008
Drug Development

Array BioPharma Forms New Subsidiary Yarra Therapeutics

PAO-M01-18-NI-007
CAR T

Thermo Fisher Gets Key Customer for Its Cell Therapy Activation Reagents

PAO-M01-18-NI-006
Cell and Gene Therapy

FDA Approves Gene Therapy

PAO-M01-18-NI-005
Drug Delivery

Building DNA and RNA Origami for Drug Delivery

PAO-M01-18-NI-003
Acquisition

Gilead’s new Kite Subsidiary To Buy CAR-T Cell Therapy Company Cell Design Labs

PAO-M01-18-NI-001
DNA

New Method Could Provide Super Resolution for Biological Imaging

PAO-M12-17-NI-040
Drug Development

Memory T Cells Fit to be Cross Trained

PAO-M12-17-NI-027
CRISPR

Charles River Expands CRISPR Offerings with Second License

PAO-M12-17-NI-022
Cell and Gene Therapy

St. Jude Gene Therapy Improves Immunity In Babies With 'Bubble Boy' Disease

PR-M12-17-NI-008
Cell and Gene Therapy

Brammer Bio Completes Renovations at Manufacturing Site in Massachusetts

PAO-M12-17-NI-006
Regenerative Medicine

International Society for Cellular Therapy Supports New FDA Policy Framework for Regenerative Medicine

PAO-M12-17-NI-004
Strategic Partnership

New Collaboration Targets the Development of Oligonucleotides

PAO-M12-17-NI-002
Cell and Gene Therapy

Segregation in the Design of Gene Therapy Manufacturing Facilities

PAP-Q4-17-CL-002
Clinical Trials

Managing the Complexities of Outbound Clinical Drug Distribution

PAP-Q4-17-CL-001
Innovation

Developing Targeted Potassium Channel Openers for CNS-Related Therapeutics

PAP-Q4-17-CL-004
Acquistion

Kite Pharma Acquisition by Gilead Finalized

PAO-M10-17-NI-017
Cell and Gene Therapy

Gene Therapy Stabilizes Neurodegenerative Disease

PAO-M10-17-NI-013
FDA Approval

Novartis Receives First Ever FDA Approval For A CAR-T Cell Therapy, Kymriah(TM) (CTL019)

PR-M08-17-NI-010
Transient Transfection

Transient Transfection at a Large Scale for Flexibility in Clinical and Commercial Vector Manufacturing

PAP-Q3-17-CL-005
Cell and Gene Therapy

Shire Submits IND for Hemophilia A Gene Therapy

PAO-M07-17-NI-016
CDMO

Supporting the Tech Transfer Continuum for Cell & Gene Therapies

PAP-Q2-17-CL-003
CRISPR

MilliporeSigma Increases the Efficiency of Gene Editing

PAO-M05-17-NI-030
Continuous Manufacturing

Acoustics for Separation and Filtration of Applications

Stanley Kowalski III, Co-Founder, Chairman & CEO, FloDesign Sonics

PTV-M03-17-IN-008
Immuno-oncology Therapies

Combinational Immunotherapies: The Bright Future of Cancer Treatment

MCP-M04-17-NI-001
CDMO

Latest Developments in Cellular and Gene Therapies

MCP-M03-17-NI-001
Development

A New Type of Medicine: Biotherapeutics Usher in a New Era

Daniel Sikkema, VP Biologics Services, Frontage Labs

PTV-M11-16-AP-018
Biologics

Investing for Successful Advancement of Viral Vector Manufacturing

PAP-Q1-17-CL-007
Discovery

Move Toward Cell-Based Manufacturing Signals Opening in Vaccine Market

MCP-M02-17-NI-002
Biologics

Cell Line Development for Therapeutic Recombinant Proteins

MCP-M02-17-NI-001
API

A Look at Recent Pharma Industry Innovations

PAP-Q04-16-NO-001
CDMO

CDMOs Crucial for Bringing Promising Next-Generation Therapies to Market

PAP-Q03-16-CL-013
CDMO

Collaboration is the Name of the Game

PAP-Q03-16-IN-001
Biologics

Biosimilars: Are We on the Edge of a New Era of Biologics?

PAP-Q02-16-RT-002
CDMO

Achieving Large-Scale Cell and Gene Therapy Manufacturing

PAP-Q02-16-CL-010
Brammer Bio

Brammer Bio: Manufacturing Personalized

PAP-Q02-16-DL-001